Maverick Capital Ltd. Invests $3.12 Million in Medpace Holdings, Inc. $MEDP

Key Points

• Maverick Capital Ltd. has acquired a new stake in Medpace Holdings, purchasing 10,228 shares valued at approximately $3.1 million.
• Medpace's quarterly earnings surpassed analysts' expectations, reporting $3.10 earnings per share and revenue of $603.31 million, a 14.2% increase year-over-year.
• Insider trading reports indicate that significant sales were made by company executives, including a VP who sold 7,500 shares for over $3.3 million.

Maverick Capital Ltd. purchased a new stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 10,228 shares of the company's stock, valued at approximately $3,116,000.

Several other large investors have also recently bought and sold shares of MEDP. Whittier Trust Co. lifted its position in shares of Medpace by 47.3% in the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the last quarter. Benjamin Edwards Inc. lifted its position in shares of Medpace by 3.1% in the first quarter. Benjamin Edwards Inc. now owns 1,201 shares of the company's stock valued at $366,000 after buying an additional 36 shares during the last quarter. Assetmark Inc. lifted its position in shares of Medpace by 24.9% in the first quarter. Assetmark Inc. now owns 216 shares of the company's stock valued at $66,000 after buying an additional 43 shares during the last quarter. Proficio Capital Partners LLC lifted its position in shares of Medpace by 6.4% in the first quarter. Proficio Capital Partners LLC now owns 777 shares of the company's stock valued at $237,000 after buying an additional 47 shares during the last quarter. Finally, Park Avenue Securities LLC lifted its position in shares of Medpace by 1.8% in the first quarter. Park Avenue Securities LLC now owns 2,749 shares of the company's stock valued at $838,000 after buying an additional 48 shares during the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

Shares of NASDAQ MEDP traded up $4.64 during mid-day trading on Friday, hitting $486.98. 233,792 shares of the stock traded hands, compared to its average volume of 316,283. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $501.30. The company has a market cap of $13.68 billion, a PE ratio of 36.21, a price-to-earnings-growth ratio of 3.04 and a beta of 1.44. The firm has a 50 day simple moving average of $412.68 and a two-hundred day simple moving average of $344.19.

Medpace (NASDAQ:MEDP - Get Free Report) last posted its quarterly earnings data on Monday, July 21st. The company reported $3.10 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.10. Medpace had a return on equity of 67.66% and a net margin of 18.74%.The firm had revenue of $603.31 million during the quarter, compared to analyst estimates of $537.70 million. During the same period last year, the company posted $2.75 EPS. The business's quarterly revenue was up 14.2% on a year-over-year basis. Medpace has set its FY 2025 guidance at 13.760-14.53 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 12.29 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Medpace news, VP Susan E. Burwig sold 10,000 shares of the stock in a transaction on Wednesday, September 3rd. The stock was sold at an average price of $480.00, for a total transaction of $4,800,000.00. Following the sale, the vice president owned 57,500 shares in the company, valued at $27,600,000. This represents a 14.81% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO August J. Troendle sold 48,487 shares of the stock in a transaction on Monday, July 28th. The stock was sold at an average price of $451.69, for a total value of $21,901,093.03. Following the sale, the chief executive officer owned 962,615 shares in the company, valued at approximately $434,803,569.35. This represents a 4.80% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 161,266 shares of company stock valued at $74,111,427 in the last quarter. 20.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MEDP. TD Cowen reiterated a "sell" rating and set a $366.00 target price (up previously from $283.00) on shares of Medpace in a research note on Wednesday, July 23rd. William Blair reiterated a "market perform" rating on shares of Medpace in a research note on Wednesday, July 23rd. Deutsche Bank Aktiengesellschaft increased their target price on Medpace from $270.00 to $430.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. UBS Group lowered Medpace from a "neutral" rating to a "sell" rating and increased their target price for the stock from $300.00 to $305.00 in a research note on Tuesday, July 29th. Finally, Truist Financial increased their target price on Medpace from $298.00 to $436.00 and gave the stock a "hold" rating in a research note on Wednesday, July 23rd. Two investment analysts have rated the stock with a Buy rating, eleven have given a Hold rating and three have assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Reduce" and a consensus target price of $412.73.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.